Their multifaceted benefits, including significant improvements in glycemic control and weight reduction, together with cardiovascular and renal protection, have led to their widespread use across various clinical settings [8,9,10]
Hepatology 51 , 15841592 (2010)
Semaglutide has been on the market for over a decade for diabetes, and SELECT outcomes data extends past five years
Third, the optimal positioning and sequencing of GLP-1-based therapies relative to resmetirom and other emerging MASH agents (e.g., lanifibranor, pegozafermin, semaglutide combination regimens) requires dedicated combination trials, of which preliminary data from the MAESTRO-NASH secondary analysis are encouraging
[5] Any insulin dose adjustments should only be made under clinical supervision
Only a small minority, fewer than 10%, say usage of GLP-1s is viewed positively